Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Bolt Biotherapeutics, Inc. reported revenue of $8M, up 0.1% year over year. Operating margin was -469.3% and net margin -433.7%, on a free-cash-flow margin of -518.8% with capital expenditure at 0.9% of revenue. Every figure is computed directly from BOLT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $8M | -469.3% | -433.7% |
| FY2024 | $8M | -949.9% | -820.8% |
| FY2023 | $8M | -967.4% | -878.6% |
| FY2022 | $6M | -1576.6% | -1537.8% |
| FY2021 | $1M | -7364.1% | -7824.7% |
How does BOLT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.